

1 **Supplemental table.** Baseline comorbidity profiles of the study population


	Total (n = 96,595)	Asthma cohort (n = 19,319)	Control cohort (n = 77,276)	p-value
Respiratory diseases	67,129 (69.5)	19,319 (100.0)	47,810 (61.9)	< 0.01
COPD	6,172 (6.4)	3,511 (18.2)	2,661 (3.4)	< 0.01
Pneumonia	4,374 (4.5)	2,866 (14.8)	1,508 (2.0)	< 0.01
Bronchiectasis	701 (0.7)	468 (2.4)	233 (0.3)	< 0.01
NTM infection	11 (0.0)	7 (0.0)	4 (0.0)	< 0.001
Cardiovascular disease	30,618 (31.7)	7,383 (38.2)	23,235 (30.1)	< 0.01
Hypertension	23,823 (24.7)	5,626 (29.1)	18,197 (23.6)	< 0.01
Angina	4,172 (4.3)	1,242 (6.4)	2,930 (3.8)	< 0.01
Myocardial infarction	632 (0.7)	203 (1.1)	429 (0.6)	< 0.01
Congestive heart failure	1,537 (1.6)	621 (3.2)	916 (1.2)	< 0.01
Cerebrovascular disease	4,489 (4.7)	1,059 (5.5)	3,430 (4.4)	< 0.01
Endocrine diseases	23,673 (24.5)	6,111 (31.6)	17,562 (22.7)	< 0.01

Diabetes mellitus	11,767 (12.2)	2,951 (15.3)	8,816 (11.4)	< 0.01
Gastrointestinal diseases	62,892 (65.1)	16,314 (84.5)	46,578 (60.3)	< 0.01
Neurologic diseases	16,788 (17.4)	4,723 (24.5)	12,065 (15.6)	< 0.01
Mental and behavioral diseases	16,500 (17.1)	4,641 (24.0)	11,859 (15.4)	< 0.01
Musculoskeletal and connective tissue diseases	50,811 (52.6)	12,546 (64.9)	38,265 (49.5)	< 0.01
Osteoporosis	7,141 (7.4)	1,762 (9.1)	5,379 (7.0)	< 0.001
Charlson Comorbidity Index	0 (0-1)	0 (0-1)	0 (0-1)	< 0.001

2 Data are presented as number (%).

3 COPD, chronic obstructive pulmonary disease; NTM, non-tuberculous mycobacteria

4 **Supplemental figure. Flow chart**



5

6

7